NASD · Healthcare · Biotechnology · USA
Replimune Group Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapy candidates designed to activate the immune system against cancer. Its proprietary RPx platform, based on an engineered herpes simplex virus backbone, selectively kills tumors and triggers systemic anti-tumor immune responses. Lead candidates RP1 and RP2 are in clinical development for melanoma and other skin cancers.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Replimune Group Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on REPL yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.